Industry Newsroom

China Biopharma I-Mab Raises USD104m via IPO on the Nasdaq

I-Mab, a Chinese drug developer focused on autoimmune diseases, raised USD104m in an IPO on the Nasdaq. C-Bridge Capital and Hony Capital back the company. Read more»